Ranibizumab in Circulatory Disorder of Retinal Vein: an Evidence-based Approach
نویسنده
چکیده
The discovery of anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) agents is a clear breakthrough with exciting potential in medical management of retinal diseases.Ranibizumab is a humanized, affinitymatured VEGF antibody fragment that binds to and neutralizes all isoforms of VEGF, which has first received FDA approval for the treatment of macular edema due to both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). The objective of this review is to evaluate the evidence and discuss the rationale behind the recent suggestions that pharmacotherapy by Ranibizumab may be useful in the treatment of such circulatory disorder of retinal vein as a retinal vein occlusion (RVO). The available evidence suggests that repeated early frequent treatment of RVO with the anti-VEGF agent ranibizumab, gives the best chance of achieving and stabilizing both optimal anatomical and visual outcomes in the short to medium term. There is no standard protocol regarding the optimal timing of initial treatment with ranibizumab and subsequent retreatment is yet to be formulated. Where multiple injections are likely to be required, the effectiveness and safety over longer periods has yet to be determined. With more research and experience into exploring the frequency and safety of currently available agentranibizumab , it is also likely that clinicians would achieve the best protocol when dealing with patients sufferring from circulatory disorder of the retinal vein.
منابع مشابه
Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
Retinal vein occlusions (RVOs) constitute the second most common cause of retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% in persons older than 40 years of age. Despite the existence of numerous potential therapeutic options, none is entirely satisfactory, and many patients with RVO suffer irreversible visual loss. Fortunately however, the recent intr...
متن کاملRanibizumab in retinal vein occlusion: treatment recommendations by an expert panel
Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a key driver of macular oedema in RVO. In 2010, ranibizumab was approved in the USA for the treatment...
متن کاملSafety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion
Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for ...
متن کاملRecalcitrant cystoid macular oedema in an eye with ischaemic central retinal vein occlusion - what's next?
We report a case of a middle-aged gentleman with recalcitrant macular oedema (RMO) secondary to ischaemic central retinal vein occlusion (CRVO). He was given six injections of intravitreal ranibizumab (anti-VEGF) monthly. However, his visual acuity (VA) deteriorated and the macular oedema worsened. He then received an intravitreal dexamethasone implant eight months post-CRVO. His VA and macular...
متن کاملCirculatory Disorder of Branch Retinal Vein: Therapy Update
Branch retinal vein occlusion (BRVO) as a circulatory disorder of the retinal vein is the most common visually disabling disease affecting the retina after diabetic retinopathy, and is a frequent cause of vision loss and even blindness. Previously, the only treatment for this retinal vascular disease was grid laser photocoagulation, which reduces edema very slowly and provides benefit in some, ...
متن کامل